

Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala February 17, 2009

For Immediate Release

Biotage AB joins forces with MultiSynTech GmbH and enters the peptide synthesis business

Biotage today announced that the company will enter the peptide synthesis business, through two new agreements with German company MultiSynTech GmbH. The agreements concern both the distribution rights for MultiSynTech's systems and the establishment of a joint development project.

The agreements with MultiSynTech will grant Biotage distribution rights for all current MultiSynTech peptide synthesis systems. Biotage and MultiSynTech have also agreed on a joint development project to design and market a new microwave-aided peptide synthesis system, which will increase yield and speed in peptide synthesis.

Demand for synthetic peptides is currently growing rapidly. The peptide synthesizer market is estimated at SEK 150m and is growing at double digit rate. In the research phase, biochemists need increasingly longer, more complex peptides to study protein interactions, produce peptide antibodies, and understand complex disease states. As the number and complexity of peptides increase, the biochemists need new tools that offer higher productivity and increased performance.

The Biotage - MultiSynTech collaboration will create those new tools that University and biopharmaceutical peptide research groups and contract peptide labs need to meet the new challenges in peptide synthesis. Biotage will be uniquely positioned to offer both parallel synthesis and microwave synthesis capability to address the full range of needs.

“We look forward to working in close collaboration with Biotage. Biotage has a proven sales and support team that dramatically expands our coverage outside Central Europe, and really opens opportunities for our current products in USA, UK, Nordic and Asian regions.” says Udo Treffer, CEO of MultiSynTech.

“MultiSynTech is the clear leader in robotic peptide synthesis. This joint development project will combine the proven performance of the current MultiSynTech robotic synthesizer with Biotage microwave technology in a unique integrated system.” says Torben Jørgensen, CEO of Biotage.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the area of medicinal chemistry. In 2005 business and products from the company Argonaut were acquired, further strengthening the product range in medicinal chemistry. The customers include the worlds top 30 pharma companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other European countries. Biotage has 292 employees at the end of 2008 and had sales of SEK 497,8m in 2008. Biotage is listed on the OMX Nordic stock exchange. Website: www.biotage.com